α2-adrenergic receptor agonist examples

Dexmedetomidine

Mechanism of action:

(negative feedback).

Dexmedetomidine

- Presynaptic activation of the α2-adrenoceptor, inhibiting norepinephrine release, preventing entry of the neurotransmitter into the synaptic junction
- Postsynaptic activation of the α1-adrenoceptor
- inhibiting sympathetic activity. This results in decreased blood pressure and heart rate.
- Produces analgesic, sedative, and anxiolytic effects.
- Occupational exposure band (OEB) 5: control exposure to $< 1 \mu g/m^3$.

Clonidine



Mechanism of action:

- Reduces release of noradrenaline at both central and peripheral sympathetic nerve terminals.
- Produces dose-related sedation, analgesia and anxiolysis.
- A reduction in the effective dose of other anaesthetic agents and opioids is also observed.
- LC₅₀ (rat inh): 19.7 mg/m³/4 Hours
- LD₅₀ (rat i.v.): 29 mg/kg



Mechanism of action of Dexmetomidine and Clonidine.

Inhaled anaesthetic examples

Mechanism of action:

- Enhances γ-aminobutyric acid (GABA) binding to its chloride ion-channel receptor.
- The increase in intra-cellular chloride levels produces an inhibitory effect (anaesthesia).



Mechanism of action of Inhaled anaesthetics.

Toxicity Data	Oral LD∟o (Human) (µL/kg)	Oral LD ₅₀ (rat)	Inhalation LC ₅₀ (rat) [ppm]	Oral LD₅₀ (mouse) [µL/kg]	Inhalation LC ₅₀ (mouse) [ppm (3 hrs)]
Halothane	-	5680 mg/kg	29000 (1h)	-	-
lsoflurane	1071	4770 μL/kg	15300 <mark>(</mark> 3h)	5080	16800
Sevoflurane	-	10800 µL/kg	28800 (3h)	18200	28300

D_: the lowest dosage of a substance observed to cause a fatality within a specific subject population under a specific set of exposure onditions. LD_{co}: the median value of all the observed dosages of a substance resulting in a fatality within a specific subject population under a specific set of exposure conditions. LC₅₀: the median value of all the observed concentrations (based on an exposure time) of a substance resulting in a fatality within a specific subject population under a specific set of exposure conditions. Lethal dose and lethal concenration values are statistics derived from specific populations and exposure conditions (typically controlled animal studies), they may not be representative of alternate populations and/or exposure conditions.



by Sofía Sola Sancho, Maria Hemme and Ayah wafi **Office of the Science Policy Advisor**

Toxic chemicals that target the central nervous system (CNS). These chemicals can act as anaesthetics, sedatives, and analgesics. Specific CNS-acting chemicals discussed in the context of the Chemical Weapons Convention have included α2-adrenergic receptor agonists, inhaled anaesthetics, fentanils and the Schedule 2A.03* chemical BZ.

Amide group

Fentanils

- Fentanils are a highly potent family of opioid narcotic analgesic drugs.
- The family includes fentanyl, a narcotic linked to an increased risk of overdose amongst opioid addicts.
- As of May 2018, there were 20 fentanil derivatives scheduled under the Single Convention on Narcotic Drugs

Sufentanil

Carfentanil

Ocfentanil

Remifentanyl

3-Fluorofentanyl

Pivaloylfentany

α'-methyl Butyrylfentanyl

Cyclopentenilfentanyl

Cyclopropylfentanyl

para-chloro Valerylfentanyl

Valerylfentanyl

Acetylfentanyl

Furanylfentanyl

4F-iBF

Methoxyacetylfentanyl

ortho-methyl Cyclopropylfentany

Acryloylfentanyl

2'-fluoro ortho-Fluorofentanyl

hydrofuranylfentanyl (THF-F)

Properties

- · Fentanyl and its analogues are solids that require aerosolisation for weapor purposes.
- Routes of exposure for fentanils include inhalation (aerosolized form), oral exposure for fentanils include form), oral exposure for fentanils include inhalation (aerosolized form), oral exposure for fentanils include for fentanils include form), oral exposure for fentanils include for fentanils include for fentanils include form), oral exposure for fentanils include for fentanil or ingestion. Transdermal absorption is possible (for example, the use of trans patches), however as the process is slow, such that brief incidental exposures cause significant opioid toxicity. Fentanyl derivative



Mechanism of action:

- In the CNS, fentanils bind to opioid receptors, specifically µ-receptors. These receptors are found predominantly in the brain and spinal cord
- They act to depress CNS function.
- Bioavailbility from inhalation exposure can range from 12-100%.



negative feedback

prevents

release of

orepinephrine

to synapse

(e.g. Clonidine)

Halothane





Sevoflurane



- Decreased intestinal paristalsis (constipation)
- Nausea and vomiting
- Dose-dependent respiratory depression (which can lead to death)
- Diminished mental alertness resulting in a feeling of drowsiness, euphoria, sleepiness, and unconsciousness

	i sem
5	
	8.7.7.
	х.Чš

- Opioid receptor antagonists.
- tivate the receptor. • Quickly reverse signs and symptoms, especially life-threatening respiratory depres-
- might need to be readministered.
- mg have been required.



Time Weighted Average – Occupational Exposure Limits (OEL-TWA)

	· , ,
Alfentanil	1 µg/m³
Fentanyl	0.1 μg/m³
Sufentanil	0.032 µg/m³







nisation			
xposure	HEROIN	FENTANYL	CARFENTANI
nay not	- 6		H.

Fentanyl and its analogues have higher potency than morphine and heroin.

Poor drug dosage, poly-drug se and addiction are all conributors to the high rates of overdose, respiratory depres

Piperidine ring	N-Alkyl chain	Aniline ring
N Y	S Autor	
N N N N N N N N N N N N N N N N N N N	and a state	
N		F S S S S S S S S S S S S S S S S S S S
N ^V ² 22		
22 F		
N N		
N		
2. N		
N K		
N		
N Star		
N St	ALL	
N N		
S S S S S S S S S S S S S S S S S S S		F
N N N		
N R		
N		
N N		
N E	F	

Antidotes: Naloxone hydrochloride (Narcan) or Naltrexone

• Bind to the opioid receptors more strongly than a fentanyl derivative, but do not ac-

• Short half-life, symptoms may return in an apparently stabilized patient and antidotes

• 0.4 mg is the standard starting dose but for some fentanyl derivatives doses up to 2



Naltrexone

"CNS-acting

Properties

- Odourless crystalline powder with bitter taste.
- Persistent in soil and water and on most surfaces.
- Half-life in moist air ~ 3-4 weeks.

Antidote: Physostigmine

 Temporarily raises acetylcholine concentrations by binding reversibly to anticholinesterase.

Safety Ratio of BZ



Dose in [mg.min/m³]

Mechanism of action:

- · Acts as a competitive inhibitor of the neurotransmitter acetylcholine (ACh) in postsynaptic ACh receptors.
- As the concentration of BZ at these sites increases, the proportion of receptors available for binding to acetylcholine decreases, resulting in an understimulation of nerve signal transduction.
- When administered by inhalation (in aerosolised form), absorption to the bloodstream is more pronounced than with oral administration.

CNS effects:

• Stupor, ataxia, confusion, and confabulation. Induces concrete and panoramic illusions and hallucinations.

Peripheral effects:

• Mydriasis, blurred vision, dry mouth and skin, initially rapid heart rate; later, normal or slow heart rate.

Carfentani Sufentani Fentany Alfentani a- Methylfentan P- Fluorofentany Acetylfentany Morphin

Statement Statement





glycolate anticholinergic compound and is a only chemical" found in the Annex of Chemicals Weapons Convention (Schedule

2A.03*)



Presynaptic

The large difference between the median lethal concentration (LC_{150}) and the median incapacitating concentration (IC₊₊₀) allows for the onset of CNS-acting symptoms to appear at a dosage much lower than a lethal dose.

Choline (Ch)

Acetic acid 🛛 🕭

CoA) = Coenzyme A

AChE = Acetylcholinesterase

Mechanism of action of BZ.

Acetylcholine

receptor

Postsynaptic

cell